BR112014013175A2 - composições de liberação prolongada baseadas em lipídios anfipáticos - Google Patents

composições de liberação prolongada baseadas em lipídios anfipáticos

Info

Publication number
BR112014013175A2
BR112014013175A2 BR112014013175A BR112014013175A BR112014013175A2 BR 112014013175 A2 BR112014013175 A2 BR 112014013175A2 BR 112014013175 A BR112014013175 A BR 112014013175A BR 112014013175 A BR112014013175 A BR 112014013175A BR 112014013175 A2 BR112014013175 A2 BR 112014013175A2
Authority
BR
Brazil
Prior art keywords
release compositions
prolonged release
amphipathic lipid
compositions
amphipathic
Prior art date
Application number
BR112014013175A
Other languages
English (en)
Other versions
BR112014013175B1 (pt
BR112014013175A8 (pt
Inventor
A Howard Scott
Purvis Troy
Original Assignee
Pegasus Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pegasus Laboratories Inc filed Critical Pegasus Laboratories Inc
Publication of BR112014013175A2 publication Critical patent/BR112014013175A2/pt
Publication of BR112014013175A8 publication Critical patent/BR112014013175A8/pt
Publication of BR112014013175B1 publication Critical patent/BR112014013175B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "composições de liberação prolongada baseadas em lipídios anfipáticos". a presente invenção refere-se a composições mastigáveis de liberação prolongada, bem como seus métodos de produção são fornecidos. as composições de liberação prolongada contêm lipídios anfipáticos, os quais são usados para encapsular vários fármacos e ingredientes ativos.
BR112014013175-9A 2011-12-02 2012-11-30 Processo para preparar comprimidos de composição de liberação prolongada BR112014013175B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161566279P 2011-12-02 2011-12-02
US61/566,279 2011-12-02
PCT/US2012/067361 WO2013082470A1 (en) 2011-12-02 2012-11-30 Amphipathic lipid-based sustained release compositions

Publications (3)

Publication Number Publication Date
BR112014013175A2 true BR112014013175A2 (pt) 2017-06-13
BR112014013175A8 BR112014013175A8 (pt) 2021-06-08
BR112014013175B1 BR112014013175B1 (pt) 2022-08-09

Family

ID=48524178

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013175-9A BR112014013175B1 (pt) 2011-12-02 2012-11-30 Processo para preparar comprimidos de composição de liberação prolongada

Country Status (8)

Country Link
US (1) US9248096B2 (pt)
EP (1) EP2785333A4 (pt)
JP (1) JP2015500241A (pt)
AU (1) AU2012345726B2 (pt)
BR (1) BR112014013175B1 (pt)
CA (1) CA2854054C (pt)
MX (1) MX351453B (pt)
WO (1) WO2013082470A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531671A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017048859A1 (en) * 2015-09-16 2017-03-23 Corr-Jensen, Inc. Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates
LT3350157T (lt) 2015-09-17 2022-02-25 Modernatx, Inc. Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
AU2016366978B2 (en) 2015-12-10 2022-07-28 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
EP4036079A3 (en) 2015-12-22 2022-09-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN110520409A (zh) 2017-03-15 2019-11-29 摩登纳特斯有限公司 用于细胞内递送治疗剂的化合物和组合物
EP3595727A1 (en) 2017-03-15 2020-01-22 ModernaTX, Inc. Lipid nanoparticle formulation
DK3596042T3 (da) 2017-03-15 2022-04-11 Modernatx Inc Krystalformer af aminolipider
US20190110988A1 (en) * 2017-10-17 2019-04-18 Lemulsa Technologies Inc. Delivery System That Utilizes Liposomal or Emulsion Vehicles
MX2021005888A (es) 2018-11-26 2021-06-23 Procter & Gamble Preparacion farmaceutica solida que contiene acido lipoico y uso de esta.
CN114728887A (zh) 2019-09-19 2022-07-08 摩登纳特斯有限公司 用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6348226A (ja) * 1986-08-14 1988-02-29 Ono Pharmaceut Co Ltd 徐放性を有する経口投与用固形製剤
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US6077534A (en) * 1997-09-02 2000-06-20 Klinge Pharma Gmbh Production of pharmaceutical formulations for treatment of edema and venous disorders
DE19740983A1 (de) * 1997-09-18 1999-04-08 Warner Lambert Co N D Ges D St Verfahren zur Erschwerung der Extraktion von Wirkstoffen aus Tabletten
US6723358B1 (en) 1998-03-23 2004-04-20 General Mills, Inc. Encapsulation of components into edible products
ATE251449T1 (de) * 1999-06-14 2003-10-15 Cosmo Spa Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
US7314640B2 (en) 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
PL204079B1 (pl) * 2004-08-12 2009-12-31 Inst Farmaceutyczny Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania
ATE476176T1 (de) * 2007-03-02 2010-08-15 Farnam Co Inc Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
US8404275B2 (en) 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
CN102202654B (zh) * 2008-09-04 2014-07-30 法纳姆公司 可咀嚼的缓释制剂
EA024365B1 (ru) * 2009-05-28 2016-09-30 Крка, Товарна Здравил, Д.Д., Ново Место Фармацевтическая композиция, содержащая тамсулозин, и способ ее получения

Also Published As

Publication number Publication date
CA2854054A1 (en) 2013-06-06
EP2785333A4 (en) 2015-04-01
MX351453B (es) 2017-10-16
EP2785333A1 (en) 2014-10-08
US20130142876A1 (en) 2013-06-06
US9248096B2 (en) 2016-02-02
CA2854054C (en) 2020-05-12
NZ624641A (en) 2016-04-29
AU2012345726A1 (en) 2014-05-29
BR112014013175B1 (pt) 2022-08-09
BR112014013175A8 (pt) 2021-06-08
WO2013082470A1 (en) 2013-06-06
MX2014006271A (es) 2014-09-22
JP2015500241A (ja) 2015-01-05
AU2012345726B2 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
BR112014013175A2 (pt) composições de liberação prolongada baseadas em lipídios anfipáticos
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
CL2014003475A1 (es) Forma c cristalina de acido obeticolico; proceso de preparacion de la forma 1 de acido obeticolico a partir de la forma c cristalina; composicion farmaceutica que comprende a una forma cristalina de acido obeticolico, util para el tratamiento o prevencion de una enfermedad hepatica colestasica, hepatopatia alcoholica y enfermedades cardiovasculares tal como aterosclerosis, entre otras.
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
WO2012170889A8 (en) Cleavable lipids
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
CO7240369A2 (es) Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
TR201816986T4 (tr) Terapötik ajan iletim formülasyonlarına yönelik lipitler.
MX2016007067A (es) Microcapsulas lipidicas que comprenden de preferencia un retinoide y composicion que las contiene, su procedimiento de preparacion y su uso en dermatologia.
BR112015028853A2 (pt) Composição detergente com ph baixo
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
BR112015011430A2 (pt) composição para liberação imediata e prolongada
CO6710926A2 (es) Compuestos de n-heteroarilo
EA201391212A1 (ru) Новые применения хлорида холина в агрохимических препаратах
BR112012028773A2 (pt) composições farmacêuticas compreendendo hidromorfona e naloxona
RS53783B1 (en) INHALATION MEDICINAL PRODUCTS INCLUDING TIOTROPIUM
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
SMT201500235B (it) Formulazione comprendente derivato di fenilamminopirimidina come agente attivo
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
BR112013028607A2 (pt) composições sólidas contendo éter glicólico e água
BR112013019924A8 (pt) Composições para cuidado oral
AR094224A1 (es) Composicion farmaceutica en forma de una suspension oral

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/11/2012, OBSERVADAS AS CONDICOES LEGAIS